PD-1/PD-L1 抑制剂在晚期结直肠癌联合治疗中的研究进展
唐圣， 任庆兰 - 中国肿瘤临床, 2019 - cjco.cn
… resistant to immunotherapy, and the mechanism of resistance may be associated with the
lack of CD8 + T lymphocytes in the tumor microenvironment. Combined immunotherapy can …
lack of CD8 + T lymphocytes in the tumor microenvironment. Combined immunotherapy can …
特瑞普利单抗治疗黑色素瘤的适应证分析
唐碧霞， 斯璐， 郭军 - 中国肿瘤临床, 2019 - cjco.cn
… Abstract: On December 27, 2018, the first domestic anti-PD-1 … in the field of tumor
immunotherapy. In this article, we … global development of other anti-PD-1 antibodies, to provide …
immunotherapy. In this article, we … global development of other anti-PD-1 antibodies, to provide …
溶瘤病毒抗肿瘤治疗的临床应用进展
王磊， 霍彬， 霍小东， 王海涛 - 中国肿瘤临床, 2021 - cjco.cn
… , immunotherapy, represented by immune checkpoint inhibitors, has achieved great success
as an anti-tumor therapy. Oncolytic virus (… , providing us with a better understanding of the …
as an anti-tumor therapy. Oncolytic virus (… , providing us with a better understanding of the …
[HTML][HTML] MSS 型结直肠癌免疫联合治疗研究进展
尹竺晟， 梁新军 - 肿瘤防治研究, 2022 - html.rhhz.net
… Therefore, strategies to improve the efficacy of immunotherapy … progress on combined
immunotherapy for MSS mCRC. … 近年来,包括细胞毒性T淋巴细胞相关蛋白4(cytotoxic T lymphocyte…
immunotherapy for MSS mCRC. … 近年来,包括细胞毒性T淋巴细胞相关蛋白4(cytotoxic T lymphocyte…
免疫检查点抑制剂在肺淋巴上皮瘤样癌等病毒相关肿瘤中的研究进展
钟育敏， 张绪超 - 循证医学, 2021 - jebm.cn
… (PD⁃L1)and sufficient lymphocytic infiltration,it was likely that immunotherapy could be a …
进展的PLELC 患者中T 细胞免疫球蛋白域粘蛋白域蛋白⁃ 3(T cells immunoglobulin domain and …
进展的PLELC 患者中T 细胞免疫球蛋白域粘蛋白域蛋白⁃ 3(T cells immunoglobulin domain and …
干细胞样CD8+T细胞在抗肿瘤免疫治疗中的地位与演进效应
林果， 姚卓然， 王徽， 纳飞飞， 卢铀 - 中国肿瘤临床, 2023 - cjco.cn
… action of stem-like CD8+T cells in anti-tumor immunotherapy … infiltrating lymphocytes,TILs)[9].肿瘤
抗 原暴露的持续时间是… 因子T 细胞因 子1(T cell factor 1,TCF1)”为标志(TCF1 由T 细胞 …
抗 原暴露的持续时间是… 因子T 细胞因 子1(T cell factor 1,TCF1)”为标志(TCF1 由T 细胞 …
[PDF][PDF] 免疫治疗在胶质瘤的研究进展
包士峰， 王春红， 吉宏明 - 国际神经病学神经外科学杂志, 2023 - jinn.org.cn
… cell;NK cell;oncolytic virus … 目前胶质瘤的免疫治疗研究 主要包括疫苗治疗,免疫检查点治疗,嵌
合抗原受体T 细 胞免疫治疗(chimeric antigen receptor T cell immunotherapy,CAR-T),自然杀伤(…
合抗原受体T 细 胞免疫治疗(chimeric antigen receptor T cell immunotherapy,CAR-T),自然杀伤(…
[HTML][HTML] 肺癌免疫检查点抑制剂的联合治疗研究进展
郭寒菲， 白日兰， 崔久嵬 - Chinese Journal of Lung Cancer, 2020 - ncbi.nlm.nih.gov
… 细胞毒性T淋巴细胞相关抗原4（cytotoxic T lymphocyte … 点抑制剂靶点，pembrolizumab、nivolumab、atezolizumab、durvalumab…
溶瘤病毒（oncolytic virus, OV）通过基因工程手段减毒增效，可…
溶瘤病毒（oncolytic virus, OV）通过基因工程手段减毒增效，可…
[HTML][HTML] 组织驻留记忆T 细胞在肺癌中的研究进展
谈思含， 田攀文 - Chinese Journal of Lung Cancer, 2022 - ncbi.nlm.nih.gov
… associated with cytotoxicity and enhances T cell (antigen) … and prognosis of immunotherapy
in lung cancer patients. This … (+) tumor-infiltrating lymphocytes with a resident memory …
in lung cancer patients. This … (+) tumor-infiltrating lymphocytes with a resident memory …
[HTML][HTML] 肝癌免疫治疗的研究进展
沈宗毅， 李卯晨， 白素杭， 杨庆坤， 张富涵， 唐茂… - 生物工程 …, 2019 - cjb.ijournals.cn
… cancer research. This article reviews the research progress of immunotherapy for liver cancer.
… frequency ablation on T lymphocyte subsets in patients with primary liver cancer. Chin J …
… frequency ablation on T lymphocyte subsets in patients with primary liver cancer. Chin J …